Alexanders logo

AlexandersNYSE: ALX

Profile

Industry:

Retail

Country:

United States

IPO:

21 February 1973

Next earnings report:

12 February 2025

Last dividends:

08 November 2024

Next dividends:

N/A
$1.12 B
-18%vs. 3y high
46%vs. sector
-7%vs. 3y high
41%vs. sector
-17%vs. 3y high
94%vs. sector
-29%vs. 3y high
54%vs. sector

Price

after hours | Tue, 19 Nov 2024 22:05:00 GMT
$220.00+$1.90(+0.87%)
$55.67 M$55.20 M
$55.67 M$6.68 M

Analysts recommendations

Institutional Ownership

ALX Latest News

Alexander's Is A Good Business That The Market Has Overestimated
seekingalpha.com12 November 2024 Sentiment: NEUTRAL

Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.

Alexander's (ALX) Tops Q3 FFO and Revenue Estimates
zacks.com04 November 2024 Sentiment: POSITIVE

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.

Alexander's Announces Third Quarter Financial Results
globenewswire.com04 November 2024 Sentiment: NEUTRAL

PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported:

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
globenewswire.com01 November 2024 Sentiment: POSITIVE

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers

Alexander's Declares Quarterly $4.50 Dividend on Common Shares
globenewswire.com30 October 2024 Sentiment: POSITIVE

PARAMUS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 29, 2024 to stockholders of record on November 11, 2024.

Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
globenewswire.com22 October 2024 Sentiment: POSITIVE

PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens.

Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.
newsfilecorp.com11 October 2024 Sentiment: POSITIVE

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - October 11, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3)  ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a binding arrangement agreement (the "Arrangement Agreement") dated October 11, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Transaction"). The Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in sixteen (16) uranium exploration projects that total approximately 220,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake.

Alexander's Completes $400 Million Refinancing of 731 Lexington Avenue Office Condominium
globenewswire.com30 September 2024 Sentiment: POSITIVE

PARAMUS, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it has completed a $400 million refinancing of the office condominium portion of 731 Lexington Avenue, the Class A Bloomberg LP headquarters building. The interest-only loan carries a fixed rate of 5.045% and matures in October 2028. The loan is prepayable, at Alexander's option, with no penalty, beginning in October 2026.

New Strong Buy Stocks for September 18th
zacks.com18 September 2024 Sentiment: POSITIVE

SN, ALX, BPOP, ARCAY and JSAIY have been added to the Zacks Rank #1 (Strong Buy) List on September 18, 2024.

Best Income Stocks to Buy for September 13th
zacks.com13 September 2024 Sentiment: POSITIVE

BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024.

  • 1(current)
  • 2
  • 3

What type of business is Alexanders?

Alexander's, Inc. (NYSE: ALX) is a real estate investment trust (“REIT”), incorporated in Delaware, engaged in leasing, managing, developing and redeveloping its properties. All references to “we,” “us,” “our,” “Company” and “Alexander's” refer to Alexander's, Inc. and its consolidated subsidiaries. We are managed by, and our properties are leased and developed by, Vornado Realty Trust (“Vornado”) (NYSE: VNO). We have five properties in New York City.

What sector is Alexanders in?

Alexanders is in the Real Estate sector

What industry is Alexanders in?

Alexanders is in the Retail industry

What country is Alexanders from?

Alexanders is headquartered in United States

When did Alexanders go public?

Alexanders initial public offering (IPO) was on 21 February 1973

What is Alexanders website?

https://www.alx-inc.com

Is Alexanders in the S&P 500?

No, Alexanders is not included in the S&P 500 index

Is Alexanders in the NASDAQ 100?

No, Alexanders is not included in the NASDAQ 100 index

Is Alexanders in the Dow Jones?

No, Alexanders is not included in the Dow Jones index

When was Alexanders the previous earnings report?

No data

When does Alexanders earnings report?

The next expected earnings date for Alexanders is 12 February 2025